Evaluation of Air Polishing With Ultrasonic Debridement in the Treatment of Initial Periodontal Pockets

May 12, 2020 updated by: Syrian Private University

Clinical Outcomes of Using Erythritol Powder by Means of Air Polishing With Ultrasonic Debridement in the Treatment of Initial Periodontal Pockets in Hand of Dental Students: A Split-mouth, Randomized, Comparative, Controlled Study

Clinical evaluation of using erythritol powder as air polishing with ultrasonic scaling and root planing in the treatment of initial periodontal pockets. This trial will be split-mouth design, in which each patient will receive traditional treatment (ultrasonic mechanical therapy and polishing) in one side, while the contralateral two quadrants of the jaws will be treated with erythritol powder by means of air polishing and ultrasonic scaling and root planing.

Study Overview

Detailed Description

The aim of the study is to evaluate the usage of erythritol powder by means of air polishing in hand of undergraduate dental students as a single way to remove biofilm and the adjunctive application of ultrasonic piezo afterward for calculus removal and root planing only in the treatment of initial periodontal pockets.

The sample size will be 15 patients. Initially, oral hygiene instructions with scaling and root planing will consist of the treatment phase. Each subject will be informed comprehensively about oral hygiene instructions using disclosing solution (such as erythrosine) and hand mirror. The participant will be shown modified bass technique and the proper usage of dental floss and appropriate interdental brushes.

The control side will be treated with supra- and subgingival ultrasonic piezo scalers then supragingival polishing with rubber cup and a special fluoride containing paste as a traditional way of removal of plaque and calculus, while the test side, will be confined to erythritol powder by means of air polishing as the only way to remove ultrasonic piezo scalers.

At the end of treatment, hand instruments may be used to ensure the smoothness 0f the teeth surfaces.

Clinical measurements will be performed at baseline and at 2 weeks, 4 and 6 weeks for the plaque index and gingival indices, whereas probing will be performed only after 6 weeks.

Study Type

Interventional

Enrollment (Actual)

13

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 60 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Patients are in generally good health
  2. Patients are from both gender and their age is between 18 to 60 years.
  3. Patients have a minimum of 20 teeth
  4. The patient is a non-smoker (less than 5 cigarettes per day) and non-alcoholic.
  5. Female participants must not be pregnant or breastfeeding (lactation).
  6. the absence of severe oral habits
  7. the presence of at least one residual pocket with pocket depth >4 mm with interdental sites with a probing depth of 3 to 5 mm without furcation involvement or subgingival restorations.
  8. A sign informed consent from participation and permission to use obtained data for research purposes.

Exclusion Criteria:

  1. Bruxism
  2. Allergy to glycine or chlorhexidine;
  3. systemic medical conditions requiring antibiotic prophylaxis (for endocarditis prophylaxis) and anti-inflammatory drugs before dental procedures;
  4. active systemic infectious disease;
  5. major systemic illnesses (diabetes mellitus, cancer, immunodeficiency virus, bone metabolic diseases or disorders that compromise wound healing, radiation or immunosuppressive therapy, neutropenia, agranulocytosis, or bleeding disorders.
  6. chronic high dose steroid therapy
  7. Patients are undergone to radiotherapy or chemotherapy before or during the study period.
  8. actively smoking more than five cigarettes per day;
  9. signs of generalized severe periodontitis;
  10. having received periodontal maintenance within 3 months before baseline
  11. patients treated with antibiotics 6 months prior to the study
  12. chronic bronchitis and asthma
  13. compromised immune system
  14. hypersensitivity to sugar alcohols.
  15. any physical limitations or restrictions that might preclude normal oral hygiene procedures.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: An erythritol powder
An erythritol powder will be used by Electro Medical Systems AIRFLOW® and then Electro Medical Systems Piezo will be used for supra- and subgingival ultrasonic instrumentation
An erythritol powder will be used by Electro Medical Systems AIRFLOW® and then Electro Medical Systems Piezo will be used for supra- and subgingival ultrasonic instrumentation
Electro Medical Systems Piezo will be used for supra- and subgingival ultrasonic instrumentation
Active Comparator: ultrasonic instrumentation
Electro Medical Systems Piezo will be used for supra- and subgingival ultrasonic instrumentation
Electro Medical Systems Piezo will be used for supra- and subgingival ultrasonic instrumentation

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
change in the papillary bleeding index
Time Frame: baseline, 2-weeks, 4-weeks, 6-weeks after the treatment

Probing is performed in all four quadrants. A quadrant 1 is probed only from the oral aspect, quadrant 2 from the facial, 3 again from oral, and from the facial in quadrant 4

Grade 1-Point: 20-30 seconds after probing the mesial and distal sulci with a periodontal probe, a single bleeding point is observed.

Grade 2-Line/Points: A fine line of blood or several bleeding points become visible at the gingival margin.

Grade 3-Triangle: The interdental triangle becomes more or less filled with blood.

Grade 4-Drops: Profuse bleeding. Immediately after probing, blood flows into the interdental area to cover portions of the tooth and/or gingiva.

Calculation:

Papillary bleeding index= Bleeding Number/ Number of sites measured

baseline, 2-weeks, 4-weeks, 6-weeks after the treatment
change in the percentage of study sites positive for bleeding on probing
Time Frame: baseline, 6-weeks after the treatment

All four surfaces of all teeth are assessed with regard to whether probing elicits bleeding (+) or not (-). The severity of gingivitis is expressed as a percentage.

- no bleeding upon probing (not recorded)

+ bleeding upon probing

Calculation:

Bleeding on probing= Number of bleeding sites x100 / Number of sites evaluated

baseline, 6-weeks after the treatment

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
change in the full mouth Plaque Index
Time Frame: baseline, 2-weeks, 4-weeks, 6-weeks after the treatment

a score of 0 to 5 is assigned to each facial and lingual unrestored surface of all the teeth except third molars, as follows: The Plaque Index System

Scores Criteria

  • 0 No plaque
  • 1 Separate flecks of plaque at the cervical margin of the tooth
  • 2 A thin continuous band of plaque (up to one mm) at the cervical margin of the tooth
  • 3 A band of plaque wider than one mm but covering less than one-third of the crown of the tooth
  • 4 Plaque covering at least one-third but less than two-thirds of the crown of the tooth
  • 5 Plaque covering two-thirds or more of the crown of the tooth
baseline, 2-weeks, 4-weeks, 6-weeks after the treatment
change in the Calculus index
Time Frame: baseline, 2-weeks, 4-weeks, 6-weeks after the treatment
  • 0, no calculus;
  • 1, mild supragingival calculus extending to marginal gingiva is present;
  • 2, moderate supra and subgingival calculus or only subgingival calculus is present; and
  • 3, excessive supra and subgingival calculus is present.

it will be estimated visually

baseline, 2-weeks, 4-weeks, 6-weeks after the treatment
change in the Modified Gingival Index
Time Frame: baseline, 2-weeks, 4-weeks, 6-weeks after the treatment
  • 0 = Normal gingiva;
  • 1 = Mild inflammation - slight change in color and slight edema;
  • 2 = Moderate inflammation - redness, edema and glazing;
  • 3 = Severe inflammation - marked redness and edema, ulceration with tendency to spontaneous bleeding.

it will be estimated visually

baseline, 2-weeks, 4-weeks, 6-weeks after the treatment
change in the Probing pocket depth
Time Frame: baseline, 6- weeks after the treatment
measure as the change in distance from the gingival margin to the bottom of the gingival sulcus by using a periodontal probe (UNC 15 "University of North Carolina")
baseline, 6- weeks after the treatment
The change of the root sensitivity
Time Frame: baseline, 24- hours, 48- hours, 72-hours, 1- week, 2-weeks, 4-weeks, 6-weeks after the treatment
will be evaluated using a visual analogue scale (VAS). The VAS root sensitivity scores ranges between 0 to 10. (0: no root sensitivity, 5: moderate root sensitivity, 10: severe root sensitivity).
baseline, 24- hours, 48- hours, 72-hours, 1- week, 2-weeks, 4-weeks, 6-weeks after the treatment

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Hala Albonni, DDS MSc, Syrian Private University
  • Study Chair: Hazem Sawaf, DDS MSc PhD, Syrian Private University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 9, 2019

Primary Completion (Actual)

September 30, 2019

Study Completion (Actual)

December 30, 2019

Study Registration Dates

First Submitted

February 18, 2019

First Submitted That Met QC Criteria

March 2, 2019

First Posted (Actual)

March 5, 2019

Study Record Updates

Last Update Posted (Actual)

May 14, 2020

Last Update Submitted That Met QC Criteria

May 12, 2020

Last Verified

May 1, 2020

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Gingivitis

Clinical Trials on Electro Medical Systems AIRFLOW®

3
Subscribe